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ABSTRACT: Using activity-based protein proﬁling (ABPP),
functional proteins can be interrogated in their native
environment. Despite their pharmaceutical relevance, G
protein-coupled receptors (GPCRs) have been diﬃcult to
address through ABPP. In the current study, we took the
prototypical human adenosine A2A receptor (hA2AR) as the
starting point for the construction of a chemical toolbox
allowing two-step aﬃnity-based labeling of GPCRs. First, we
equipped an irreversibly binding hA2AR ligand with a terminal alkyne to serve as probe. We showed that our probe irreversibly
and concentration-dependently labeled puriﬁed hA2AR. Click-ligation with a sulfonated cyanine-3 ﬂuorophore allowed us to
visualize the receptor on SDS-PAGE. We further demonstrated that labeling of the puriﬁed hA2AR by our probe could be
inhibited by selective antagonists. Lastly, we showed successful labeling of the receptor in cell membranes overexpressing
hA2AR, making our probe a promising aﬃnity-based tool compound that sets the stage for the further development of probes for
GPCRs.
■ INTRODUCTION
The adenosine receptors, belonging to the family of G protein-
coupled receptors (GPCRs), have been coined adenosine A1,
A2A, A2B, and A3. These receptors are widely distributed
through the human body and are considered promising targets
for a wide range of diseases.1 Regadenoson, a selective human
adenosine A2A receptor (hA2AR) agonist used to increase
vasodilation during cardiac imaging, has been approved by the
FDA, exemplifying the potential therapeutic applications for
the hA2AR. Likewise, hA2AR antagonists are currently being
pursued as potential treatment of Parkinson’s disease2 and as
adjuvants in cancer immunotherapy.3
The hA2AR was one of the ﬁrst GPCRs for which a crystal
structure was elucidated.4 However, the challenges in structural
biology of GPCRs, including the low expression level in native
tissue and inherent poor protein stability,5 still exist. To
overcome these obstacles, covalent probes have been
developed as useful pharmacological tools. Such probes, also
named aﬃnity labels, represent compounds that feature a
reactive cross-linking moiety, which can irreversibly and
speciﬁcally bind to a receptor. For example, an irreversible
antagonist was used to stabilize the adenosine A1 receptor for
cocrystallization, resulting in the visualization of key amino
acids important for ligand−receptor binding.6
The design of covalent probes for GPCRs generally follows a
similar strategy, which is to incorporate a warhead in a high-
aﬃnity, reversibly binding ligand. Based on the type of warhead
used, two categories of irreversible ligands can be discerned:
photoaﬃnity and chemoreactive ligands.7,8 Whereas in the
former type a photoreactive warhead is employed, the latter is
equipped with an electrophilic chemical moiety capable of
binding nucleophilic residues in the target protein. A
commonly used warhead is aryl sulfonyl ﬂuoride, which is
capable of covalently binding to many nucleophilic amino acid
residues, such as serine, threonine, lysine, and cysteine.9 This
warhead has been incorporated in several reported covalent
ligands for the adenosine receptors, including FSCPX,10
FSPTP,11 ﬂuorosulfonyl-functionalized pyrimidine deriva-
tives,12 and LUF7445.13 Likewise, ﬂuorescent tags have been
incorporated into adenosine receptor ligands to visualize the
receptor, which yielded, e.g., FITC-ADAC,14 MRS5422,15 and
NBD-NECA.16 However, ﬂuorescent moieties are of signiﬁcant
size, and a priori derivatization of a ligand with such a group
may negatively aﬀect receptor aﬃnity. Here two-step aﬃnity-
based probes (AfBPs) might be a better alternative, as a
reporter tag is added after the reactive ligand has bound its
target.17
Interestingly, from the ﬁeld of activity-based protein
proﬁling (ABPP), combined with click chemistry, many
techniques have emerged that could potentially be applied to
GPCRs using our covalent ligand. Normally in ABPP, an
irreversible ligand is equipped with a ligation handle and after
binding to the protein of interest is paired with a clickable
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ﬂuorophore. In this way, via a Huisgen 1,3-dipolar cyclo-
addition, a stable triazole-linked product is formed, eﬀectively
attaching a ﬂuorescent label to the protein.18−20 Currently, this
technique serves as a tool to proﬁle the activities of drug
targets (currently mainly enzymes) in native biological
systems. One-step labeling, where the reporter group is
preattached to the probe, has been applied on GPCRs
previously.21−23 Moreover, similar two-step labeling strategies
have been applied for other targets.24,25 However, due to their
low abundance, GPCRs are diﬃcult to address with this
otherwise promising technique. Within the entire GPCR family
with over 800 members, until recently, only the mGlu5
receptor had been the subject of this approach, albeit with
limited success.26 Very recently, the type 2 cannabinoid
receptor (CB2R) has been probed with a two-step photo-
aﬃnity probe, leading to great insights into receptor local-
ization and target engagement.27
In this study, we describe our eﬀorts to obtain a clickable
aﬃnity-based probe, with an electrophilic warhead, as a logical
extension of our previous research on the successful design of a
covalent antagonist of hA2AR, compound 1 (LUF7445).
13 We
used the antagonist ZM241385 as the starting point in our
design eﬀorts and synthesized a series of ﬂuorosulfonyl
derivatives with diverse linker lengths (compounds 1−3,
Figure 1). The most potent ligand, with low nanomolar
aﬃnity, was retained for further structural modiﬁcation and
was equipped with an alkyne-click handle, resulting in probe 4,
as shown in Figure 1. We then validated that the ligand’s
binding to the receptor was wash-resistant. Additionally, we
demonstrated the ligand’s covalent labeling capacity for
Figure 1. Chemical structures of the hA2AR antagonists examined in this study. The lead compound ZM241385, a selective hA2AR antagonist,
inspired the design of covalent antagonist 1.13 In the current study, the eﬀect of the linker length between scaﬀold and warhead on aﬃnity was
further examined, yielding compound 2 and, preferably, compound 3. The aﬃnity-based probe 4 was then synthesized from compound 3, bearing
an alkyne ligation-handle and a ﬂuorosulfonyl electrophilic warhead. The electrophilic warhead is in red and the click-ligation handle is in blue.
Scheme 1. Synthesis of Compounds 2−4a
aReagents and conditions: (a) tert-butyl (4-aminobutyl)carbamate or tert-butyl (5-aminopentyl)carbamate, DiPEA, MeCN, 70−85 °C, 46−74%;
(b) TFA, quant; (c) 4-ﬂuorosulfonylbenzoyl chloride, DiPEA, MeCN, 70 °C, 2−4%; (d) Boc2O, DCM, quant; (e) PPh3, CBr4, 90%; (f)
propargylamine, DiPEA, 46%; (g) 4-ﬂuorosulfonylbenzoyl chloride, DiPEA, MeCN, quant; (h) i. 5, TFA, DCM, ii. DiPEA, MeCN, 70 °C, 45%.
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puriﬁed receptors via a bioorthogonal copper-catalyzed azide−
alkyne ligation reaction with a ﬂuorescent moiety, sulfonated
cyanine 3 ((E)-2-((E)-3-(1-(6-((3-azidopropyl)amino)-6-oxo-
hexyl)-3,3-dimethyl-5-sulfo-3H-indol-1-ium-2-yl)allylidene)-
3,3-dimethyl-1-(3-sulfopropyl)indoline-5-sulfonate). Finally,
this probe was able to proﬁle the presence of hA2AR in a
relatively complex biological sample. Hence, this is one of the
ﬁrst AfBPs for a GPCR and may set the stage for similar probes
to facilitate target discovery and bioanalysis of GPCRs
associated with human disease.
■ RESULTS AND DISCUSSION
Chemistry. Our research group has been evaluating
structural modiﬁcations of triazolotriazine derivatives based
on the selective adenosine A2A antagonist 4-(2-(7-amino-2-
(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)-
ethyl)phenol (ZM241385), to obtain a covalent ligand for the
hA2AR. The rational design of this covalent ligand originated
from a reported hA2AR crystal structure (PDB: 4EIY) in
complex with ZM241385.4 In it, the ligand binding pocket
demonstrated a deep, planar, and narrow cavity embracing the
aromatic core and furan ring of ZM241385. Therefore, an
extension of the hydroxyphenethylamine moiety into the
extracellular domain of the receptor oﬀered us the playground
for integration of the electrophilic reactive groups. Our earlier
covalent antagonist, compound 1 (Figure 1), in which the 4-
hydroxyphenylethylamine side chain in ZM241385 was
replaced with a similar side chain harboring an electrophilic
ﬂuorosulfonyl moiety, was recognized by hA2AR with an
apparent pKi of 8.99.
13 To optimize the irreversible binding
potential of our compound, with our current aim of developing
an AfBP in mind, an exploration of linker length was
performed, varying the linker between the ﬂuorosulfonyl
warhead moiety and the aromatic recognition element from
three to ﬁve carbon atoms. To this end, compounds 2 and 3
were synthesized as detailed in Scheme 1. The synthesis starts
from 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a]-
[1,3,5]triazin-7-amine 5, synthesized as previously reported,13
and involves a linear sequence comprising aromatic sub-
stitution with either commercially available mono-Boc-
protected butyldiamine or pentyldiamine and subsequent
Boc-deprotection toward intermediates 8 and 9. Introduction
of the ﬂuorosulfonylbenzoyl warhead proceeded with low
yields due to diﬃcult puriﬁcation, providing ligands 2 and 3 in
4% and 2% yield, respectively.
The synthetic route toward probe 4 (LUF7487, Figure 1) is
depicted in Scheme 1. First, the amino group of 5-
aminopentanol was protected with a Boc group and the
hydroxyl was converted to a bromide using an Appel reaction,
providing intermediate 12. Nucleophilic substitution of the
bromide with propargylamine aﬀorded amine 13, which was
acylated with 4-ﬂuorosulfonylbenzoyl chloride to give Boc-
protected bifunctional spacer 14 uneventfully. Finally, in a two-
step process, the spacer was deprotected and coupled to
scaﬀold 5, to provide probe 4 in 45% yield.
Biology. To assess the aﬃnity for the hA2AR, compounds 2
and 3 were tested in [3H]ZM241385 displacement experi-
ments (n = 3), which demonstrated a concentration-dependent
inhibition of radioligand binding to hA2AR overexpressed in
HEK293 cells. To better understand the time-dependent
binding characteristics of these compounds, we then carried
out displacement assays performed with two diﬀerent
incubation times. Representative graphs for these experiments
are given in Figure 2a and 2b, in which the concentration-
dependent inhibition of speciﬁc [3H]ZM241385 binding
shifted to the left with an incubation time extension from
0.5 h (standard) to 3 h. As detailed in Table 1, the aﬃnities of
both compound 2 and 3 signiﬁcantly increased by approx-
imately 5-fold to subnanomolar values with longer incubation
times. In other words, both designed covalent ligands became
more potent in displacing the radioligand [3H]ZM241385
from the receptor over time. Similarly to 1,13 this pronounced
aﬃnity increase may be attributed to an irreversible binding
nature of the compounds, leading to a higher receptor
occupancy with a longer incubation time. It should be kept
in mind that due to the covalent nature of the interaction,
aﬃnity values can only be apparent as no dynamic equilibrium
can be reached.
Figure 2. Displacement of speciﬁc [3H]ZM241385 binding from
HEK293 cell membranes stably expressing the hA2AR receptor at 25
°C by compound 2 (a), 3 (b), and 4 (c) with an incubation time of
0.5 h (blue curve) and 3 h (red curve), respectively. Representative
graphs are from one experiment performed in duplicate.
Table 1. (Apparent) Aﬃnities of Synthesized Ligands for
the Human Adenosine A2A Receptor
a
compoundb pKi
c (0.5 h) pKi
d (3 h) pKi shift
e
1f 8.27 ± 0.04 8.99 ± 0.01*** 0.72
2 8.20 ± 0.13 9.05 ± 0.07*** 0.85
3 8.56 ± 0.03 9.21 ± 0.01*** 0.65
4 8.41 ± 0.02 8.82 ± 0.02*** 0.41
aData are expressed as means ± SEM of three separate experiments
each performed in duplicate. ***P < 0.001 compared with the pKi
values in displacement experiments with a 0.5 h incubation time;
Student’s t test. bFor all the designed covalent antagonists, pKi values
can only be apparent, as true equilibrium cannot be reached. cAﬃnity,
expressed as pKi value, determined from displacement of speciﬁc
[3H]ZM241385 binding from the hA2AR at 25 °C during a 0.5 h
incubation. dAﬃnity, expressed as pKi value, determined from
displacement of speciﬁc [3H]ZM241385 binding from the hA2AR at
25 °C during a 3 h incubation. eAﬃnity shift was calculated as [pKi (3
h) − pKi (0.5 h)]. fData previously reported provided for
comparison.13
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Compound 3 inhibited the speciﬁc [3H]ZM241385 binding
to the hA2AR with a pKi of 9.21, compared to the aﬃnity of
compound 2 (pKi = 9.05 ± 0.07) and 1 (pKi = 8.99 ± 0.01).
Thus, the extension of the linker to ﬁve carbon atoms slightly
increased the apparent aﬃnity. This could be caused by more
steric freedom, allowing the ﬂuorosulfonyl group to orient
toward the adjacent nucleophilic residue in the receptor
binding site compared to ligands with a shorter linker. A
similar example is an electrophilic probe for the cannabinoid
CB1 receptor, 7′-NCS-1′,1′-DMH-Δ8-THC, in which length-
ening the C-3 alkyl side chain to seven carbons resulted in a
signiﬁcantly improved aﬃnity.28 Above all, high aﬃnity is a key
requirement for the development of irreversible ligands, as it
increases the presence of the chemoreactive moiety in
proximity to a nucleophilic residue in the binding site, thereby
improving receptor occupancy and causing a decrease in
nonspeciﬁc binding to other unrelated targets. As we
anticipated a greater demand for steric freedom for the
incorporation of the alkyne group and the subsequent ligation
between the alkyne moiety and a bulky ﬂuorescent dye, we
retained the preferable ﬁve-carbon atom linker length for the
design of our probe.
Inspired by the most promising compound 3, we
incorporated the alkyne click-handle to aﬀord a novel covalent
probe, compound 4 (LUF7487, Figure 1). As detailed in Table
1, aﬃnity-based probe 4 demonstrated a high aﬃnity,
displacing [3H]ZM241385 with an apparent pKi value of
8.82. Under these conditions 4 was at least 10-fold selective
over human A1 and A3 receptors (SI Table S1). In a time-
dependent study, probe 4 generated a signiﬁcant increase in
speciﬁc [3H]ZM241385 displacement over time (Table 1). In
analogy to the covalent ligand 3, the designed probe was
markedly inﬂuenced by prolonged incubation times (Figure
2c), suggesting an increasing level of covalent binding over
time. However, compared to 3, the slight decrease in aﬃnity
may be attributed to the incorporation of the click handle,
possibly leading to a steric hindrance in the ligand−receptor
complex and/or the formation of a covalent bond between the
warhead and other nucleophilic residues.
To better understand the receptor−ligand binding nature,
the novel aﬃnity-based probe was then evaluated for its
covalent nature by determining its capacity to irreversibly
block [3H]ZM241385 to hA2AR binding sites. Membranes
overexpressing hA2AR were pretreated with probe 4 or
ZM241385 at the indicated concentration (IC50 or 0.3 fold
IC50) for 3 h, followed by a three-cycle washing step to remove
the noncovalently bound material. The membranes pretreated
with probe 4 (Figure 3a) at increasing concentrations revealed
a concomitant decline in speciﬁc [3H]ZM241385 binding,
which was reduced from 65 ± 2% to 43 ± 2%. However,
membranes pretreated with the reversible antagonist
ZM241385 (Figure 3b) at increasing concentrations showed
no decrease in speciﬁc [3H]ZM241385 binding, proving that
the washing procedure was extensive enough to remove all
noncovalently binding compound. Meanwhile, the aﬃnity of
unlabeled ZM241385 was not inﬂuenced signiﬁcantly by the
preincubation and washing procedure, indicating that the
extensive washing did not damage the membrane integrity or
alter the membrane binding sites (SI Table S2). Therefore, it
could be concluded that the concentration-dependent decrease
in speciﬁc [3H]ZM241385 binding observed with probe 4
resulted from an irreversible occupancy of the hA2A receptor
binding pocket. Similar results have been obtained on other
GPCRs, e.g., for the adenosine A1 receptor irreversible
antagonist FSCPX29,30 and the covalent histamine H4 receptor
partial agonist VUF14480,31 although these compounds lack
the alkyne moiety to perform a click chemistry approach.
Fluorescent Labeling of the hA2AR. Having shown that
the designed probe 4 meets the requirement of covalent
binding, we then set out to evaluate its ability to function as an
aﬃnity-based probe. Puriﬁed hA2AR was ﬁrst incubated with
the alkyne-containing probe 4 to ensure formation of a
covalent probe−hA2AR adduct. Then all samples were
subjected to a copper(I)-catalyzed sulfonated cyanine 3-azide
(Cy3-azide) attachment to the terminal alkyne.32,33 The
subsequent ﬂuorescence scanning of a SDS-PAGE showed
that in the presence of ﬂuorescent dye Cy3-azide (Figure 4a),
probe 4 was concentration-dependently incorporated into a
ﬁxed amount of puriﬁed hA2AR, while in the absence of probe,
little ﬂuorescence intensity was detected. Importantly, Western
blot analysis using the puriﬁed hA2AR receptor and speciﬁc
antihistidine antibodies unambiguously validated that the
labeling band was hA2AR (Figure 4a). Interestingly, a second
band was observed in both aﬃnity labeling results and Western
blots, most likely resulting from posttranslationally modiﬁed
receptors,34 as has been shown previously on CB2R.
27
Quantiﬁcation of the ﬂuorescence intensity of the main
labeling bands in the hA2AR is reﬂected in the concen-
tration−eﬀect curve in Figure 4b. This revealed that clickable
probe 4 labeled hA2AR with a pEC50 value of 6.10 ± 0.04,
resulting in a maximal labeling achieved with 10 μM probe 4
when incubated with 0.1 mg mL−1 of puriﬁed hA2AR.
Collectively, these data demonstrate that probe 4 can be
used as an aﬃnity-based probe for puriﬁed hA2AR.
To further characterize our aﬃnity-based probe, we then
investigated whether competitive antagonists could inhibit the
labeling of puriﬁed receptors by probe 4. We chose to evaluate
reversible antagonist ZM241385 and irreversible compound 1,
at saturating concentrations (10 μM, i.e., 10 times higher than
the concentration of the clickable probe 4). Puriﬁed hA2AR,
preincubated with the competitors and subsequently treated as
mentioned previously to incorporate the sulfonated cyanine 3
ﬂuorophore, showed little if any ﬂuorescence intensity of
labeling bands under these conditions. This revealed that both
a reversible and an irreversible antagonist competed with probe
4 (Figure 5a, left panel) for the same binding site at the hA2AR,
which was available at identical amounts in all conditions (as
evidenced by His-tagging: Figure 5a, right panel). Theoret-
Figure 3. Probe 4 irreversibly binds to hA2AR HEK293 cell
membranes stably expressing hA2AR, and they were preincubated
with probe 4 (a) or ZM241385 (b) at the indicated comparable
concentrations. Pretreated membranes were washed three times
extensively before further displacement studies of speciﬁc [3H]-
ZM241385 binding from the hA2AR at 25 °C by nonlabeled
ZM241385 were performed. Representative graphs are from three
independent experiments performed in duplicate with error bars
representing SEM values.
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ically, both reversible and irreversible ligands inhibit aﬃnity
labeling, provided that they target the same receptor binding
site and are present in a suﬃcient concentration. Of note, in
practice, this is not always easily observed, as in the
competition between reversible ligand and covalently binding
probe there is an inherent bias toward the irreversible pathway,
hindering the interaction between the receptor and a reversible
ligand. For instance, in the few other studies where an AfBP
has been used on GPCRs it was found that a reversible mGlu5
negative allosteric modulator, MPEP, could not inhibit the
tandem photoaﬃnity labeling of puriﬁed mGlu5, whereas on
CB2R, inhibition of labeling by various competitors was
observed.26,27 Apparently, this was less of a problem on the
hA2AR. Our results demonstrate that the developed AfBP
system can serve as an eﬀective chemical tool for proﬁling the
puriﬁed hA2AR in vitro, prompting us to further evaluate the
potency and selectivity of probe 4 in proﬁling the activity of
the adenosine A2A receptor in more complex biological
samples.
We further explored the ability of probe 4 to label hA2AR in
cell membranes prepared from HEK293 cells, which were
transiently transfected with N-terminally FLAG-tagged and C-
terminally His-tagged human adenosine A2A receptors (FLAG-
hA2AR-His). Therefore, FLAG-hA2AR-His cell membranes
were incubated with probe 4 at room temperature for 1 h,
followed by click ligation to Cy3-azide treatment. As detailed
in Figure 6, a band corresponding to the molecular weight of
the FLAG-hA2AR-His was observed upon ﬂuorescent SDS-
PAGE scanning, which was then validated by Western blot
using speciﬁc anti-FLAG antibodies. In these initial proof-of-
concept experiments we highlighted the versatility of probe 4,
which can be eﬃciently used to label the adenosine A2A
receptor in cell membrane samples.
Background signals caused by nonspeciﬁc labeling of
abundant proteins in the complex proteomes may sometimes
confound the analysis of on-target labeling of low expression
proteins such as GPCRs. Thus, we utilized cell membranes
transiently transfected with FLAG-hA2AR-His, which have a
relatively high level of receptor expression. Additionally,
instead of premixing the copper sulfate and sodium ascorbate
reagents, we slightly altered the click procedure by adding the
copper sulfate last to achieve eﬃcient and selective labeling of
the A2A receptors.
35,36 Although we were able to decrease the
strong background signals, a signiﬁcant nonspeciﬁc labeling
was still observed. Several explanations may be put forward,
such as a low eﬃciency of the click reaction between the
ﬂuorescent dyes and labeled receptors, nonspeciﬁc protein
binding of the probe due to the inherently reactive warhead,
and the sensitivity of the used detection method. Hence,
further technological reﬁnement should help us in achieving
better labeling of endogenously expressed GPCRs, e.g., in
human tissues as has been shown recently on CB2R.
27 The
monitoring of endogenous GPCR expression and target
engagement in human cells holds promise for future GPCRs
studies.
■ CONCLUSION
Starting from a selective antagonist, ZM241385, we designed
and synthesized a series of covalent ligands using the
electrophilic nature of sulfonyl ﬂuorides, eventually yielding
probe 4, the ﬁrst aﬃnity-based probe for the hA2AR. We
successfully demonstrated a concentration-dependent labeling
of puriﬁed receptor by probe 4 via an experimental two-step
labeling strategy, which could be inhibited by both reversible
and irreversible competing ligands. Additionally, probe 4
displayed target selectivity in cell membranes overexpressing
the hA2AR, indicating that it may become a useful
Figure 4. Concentration-dependent aﬃnity labeling of puriﬁed, His-tagged hA2AR by probe 4. (a) Puriﬁed hA2AR material was incubated with the
indicated concentrations of probe 4 or vehicle (1% DMSO) and subjected to click chemistry ligation with Cy3-azide, followed by SDS-PAGE
separation and in-gel ﬂuorescence scanning (left). The blotted membranes were probed with antihistidine antibody, wherein bands corresponding
to puriﬁed hA2AR molecular weight (∼47 kDa) were evident in all samples (right). (b) Quantiﬁcation of ﬂuorescence intensity from puriﬁed hA2AR
labeled by probe 4 clicked to Cy3-azide. Representative graphs are from three independent experiments, with errors bars representing SEM values.
In-gel ﬂuorescence of the hA2AR band at ∼47 kDa was normalized to the corresponding hA2AR immunoreactivity in each sample.
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pharmacological tool to identify the hA2AR in living organisms
for target validation or to assess receptor subtype distribution.
In this strategy a probe depicts the native binding with less
perturbation, which bridges the chemical biology study with
molecular pharmacology to better investigate receptor−ligand
interactions.
In future research, diﬀerent tags may be introduced; for
instance a biotin-tag would allow for streptavidin-mediated
receptor enrichment followed by LC/MS analysis. Similarly,
the approach developed in this study may be applied to other
GPCRs, such as the other adenosine receptor subtypes.
■ EXPERIMENTAL SECTION
Chemistry. All solvents and reagents were purchased from
commercial sources and were of analytical grade. 1H NMR spectra
were recorded on a Bruker AV 400 liquid spectrometer (1H NMR,
400 MHz) at ambient temperature. Chemical shifts are reported in
parts per million (ppm) and are designated by δ. Coupling-constants
are reported in hertz (Hz) and are designated as J. Analytical purity of
the ﬁnal compounds was determined by high pressure liquid
chromatography (HPLC) with a Phenomenex Gemini 3 μ C18
110A column (50 × 4.6 mm, 3 μm), measuring UV absorbance at 254
nm. Sample preparation and HPLC method was as follows: 0.5 mg of
compound was dissolved in 1 mL of a 1:1:1 mixture of CH3CN/
H2O/tBuOH and eluted from the column within 15 min, with a
three-component system of H2O/CH3CN/1% TFA in H2O,
decreasing polarity of the solvent mixture in time from 80/10/10 to
0/90/10. All compounds showed a single peak at the designated
retention time and are at least 95% pure. Liquid chromatography−
mass spectrometry (LC−MS) analyses were performed using Thermo
Finnigan Surveyor − LCQ Advantage Max LC-MS system and a
Gemini C18 Phenomenex column (50 × 4.6 mm, 3 μm). The sample
preparation was the same as for HPLC analysis. The elution method
was set up as follows: 1−4 min isocratic system of H2O/CH3CN/1%
TFA in H2O, 80:10:10; from the fourth min, a gradient was applied
from 80:10:10 to 0:90:10 within 9 min, followed by 1 min of
equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer
chromatography (TLC) was routinely performed to monitor the
progress of reactions, using aluminum-coated Merck silica gel F254
plates. Puriﬁcation by column chromatography was achieved by use of
Grace Davison Davisil silica column material (LC60A 30−200 μm).
Solutions were concentrated using a Heidolph Laborota W8 2000
eﬃcient rotary evaporation apparatus and by a high vacuum on a
Binder APT line vacuum drying oven.
4-((4-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5-yl)amino)butyl)carbamoyl)benzenesulfonyl Fluoride (2). Previ-
ously synthesized N5-(4-aminobutyl)-2-(furan-2-yl)-[1,2,4]triazolo-
[1,5-a][1,3,5]triazine-5,7-diamine 8 (TFA salt, 250 mg, 0.40 mmol,
1.0 equiv) was suspended in acetonitrile (10 mL) and purged with N2.
Then DiPEA (0.42 mL, 2.4 mmol, 6.0 equiv) was added after which
4-ﬂuorosulfonylbenzoyl chloride (134 mg, 0.60 mmol, 1.5 equiv) was
added last and the mixture was heated to 70 °C for 7 h and then
stirred at room temperature for another 17 h. A ﬂash column (MTBE
+ 1% AcOH → 90% MTBE + 10% EtOAc + 1% AcOH), a
subsequent preparative TLC (1:1 MTBE:EtOAc + 1% MeOH), and
an extraction using acetonitrile (10 mL) and petroleum ether (4 × 10
mL) aﬀorded the product as a white solid (8 mg, 0.017 mmol, 4%
yield). 1H NMR (DMSO-d6, 400 MHz): δ 8.29−8.18 (m, 5H), 7.75
(s, 1H), 7.40 (br s, 2H), 7.05 (d, J = 3.2 Hz, 1H), 6.73 (m, 1H), 6.62
(s, 1H), 3.55−3.46 (m, 4H), 1.75−1.74 (m, 4H). HPLC: 96.5%, RT
7.478 min. LC-MS: [ESI + H]+: 475.20
4-((5-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5-yl)amino)pentyl)carbamoyl)benzenesulfonyl Fluoride (3). N5-(5-
Figure 5. Competitive aﬃnity labeling of the puriﬁed hA2AR by probe
4 (a) Aﬃnity labeling of puriﬁed hA2AR by probe 4 (1 μM) is
inhibited by preincubation with either compound 1 (10 μM) or
ZM241385 (10 μM) (left). The blotted membranes were probed with
antihistidine antibody, wherein bands corresponding to puriﬁed
hA2AR molecular weight (∼47 kDa) were evident in all samples
(right). (b) Quantiﬁcation of ﬂuorescence intensity from pretreated
puriﬁed hA2AR labeled by probe 4 clicked to Cy3-azide.
Representative graphs are from three independent experiments, with
errors bars representing SEM values. ***P < 0.001 compared with the
ﬂuorescent intensity of puriﬁed hA2AR labeled by probe 4 (1 μM);
Student’s t test. In-gel ﬂuorescence of the hA2AR band at ∼47 kDa was
normalized to the corresponding hA2AR immunoreactivity in each
sample.
Figure 6. Aﬃnity labeling of hA2AR in HEK293 cell membranes
transiently expressing FLAG-tagged hA2AR using probe 4. (a) Cell
membranes overexpressing FLAG-tagged hA2AR were incubated with
either 1 μM probe 4 or vehicle (1% DMSO) and then subjected to
click chemistry ligation with Cy3-azide, followed by SDS-PAGE
separation and in-gel ﬂuorescence scanning (left). The blotted
membranes were probed with anti-FLAG antibody, wherein bands
corresponding to the hA2AR molecular weight (∼50 kDa) are evident
in all samples.
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Aminopentyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine 9 (TFA salt, 674 mg, 0.85 mmol, 1 equiv) was suspended in
acetonitrile (5 mL) . 4-Fluorosulfonylbenozyl chloride (208 mg, 0.94
mmol, 1.1 equiv) was added, along with DiPEA (0.8 mL, 5 mmol, 5.8
equiv). The mixture was heated at 70 °C under N2 atmosphere for 2.5
h. A ﬂash column (DCM → 60% DCM, 40% EtOAc) with
subsequent preparative TLC (100% EtOAc) was used to obtain the
title compound as a colorless solid (9 mg, 0.018 mmol, 2% yield). 1H
NMR (C3D6O, 400 MHz): δ 8.27−8.16 (m, 4H), 7.73 (dd, J = 1.7,
0.8 Hz, 1H), 7.39 (s, 2H), 7.05 (d, J = 3.2 Hz, 1H), 6.80−6.63 (m,
1H), 6.62 (dd, J = 3.4, 1.8 Hz, 1H), 3.52−3.38 (m, 4H), 1.78−1.62
(m, 4H), 1.56−1.44 (m, 2H). HPLC: 100%, RT 7.637 min, LC-MS:
[ESI + H]+: 489.00
4-((5-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5-yl)amino)pentyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl Flu-
oride (4). tert-Butyl (5-(4-(ﬂuorosulfonyl)-N-(prop-2-yn-1-yl)-
benzamido)pentyl)carbamate 14 (586 mg, 1.38 mmol, 1 equiv) was
dissolved in DCM (10 mL). To this solution was added TFA (10
mL). After 2 min, the solvents were removed in vacuo. This crude
intermediate was suspended in acetonitrile (10 mL), and 2-(furan-2-
yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 5
(386 mg, 1.38 mmol, 1 equiv) was added, along with DiPEA (2
mL, 11.0 mmol, 8 equiv). The reaction mixture was heated at 70 °C
for 2 h. Then the reaction mixture was concentrated and puriﬁed by a
ﬂash column (EtOAc) to yield a yellow solid (330 mg, 0.62 mmol,
45%). 1H NMR (DMSO-d6, 353 K, 400 MHz,) δ 8.17 (d, J = 8.3 Hz,
2H), 7.93−7.73 (m, 5H), 7.12 (t, J = 5.3 Hz, 1H), 7.03 (d, J = 3.3 Hz,
1H), 6.64 (dd, J = 3.0, 1.5 Hz, 1H), 4.17 (s, 2H), 3.41 (s, 2H), 3.29
(d, J = 6.2 Hz, 2H), 3.14 (s, 1H), 1.73−1.61 (m, 2H), 1.61−1.44 (m,
2H), 1.40−1.23 (m, 2H) ppm. HPLC: 95.772%, RT: 8.117 min, MS:
[ESI + H]+: 527.20
tert-Butyl (4-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-
[1,3,5]triazin-5-yl)amino)butyl)carbamate (6). 2-(Furan-2-yl)-5-
(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 5 (435
mg, 1.55 mmol, 1.0 equiv), synthesized as previously reported,13 was
suspended in acetonitrile to yield a 0.1 M solution. tert-Butyl (4-
aminopropyl)carbamate (0.33 mL, 1.71 mmol, 1.1 equiv) was added,
followed by the addition of N,N-diisopropylethylamine (1.08 mL,
6.21 mmol, 4 equiv). The mixture was heated at 85 °C for 29 h and
stirred at rt for another 18 h. A ﬂash column (DCM:EtOAc, 0% →
90% EtOAc) was used to purify the crude mixture. This gave a
yellowish solid (444 mg, 1.14 mmol, 74% yield). 1H NMR (DMSO-
d6, 400 MHz): δ 8.49−7.92 (m, 2H), 7.86 (s, 1H), 7.51 (t, J = 5.9 Hz,
rotamer 1, 0.3H), 7.44 (t, J = 5.7 Hz, rotamer 2, 0.7H), 7.07−7.00 (m,
1H), 6.87−6.76 (m, 1H), 6.67 (dd, J = 3.2, 1.7 Hz, 1H), 3.29−3.19
(m, 2H), 2.92 (d, J = 6.5 Hz, 2H), 1.48 (d, J = 7.2 Hz, 2H), 1.44−
1.29 (m, 11H).
tert-Butyl (5-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-
[1,3,5]triazin-5-yl)amino)pentyl)carbamate (7). 2-(Furan-2-yl)-5-
(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 5 (280
mg, 1.0 mmol, 1.0 equiv) and commercially available tert-butyl (5-
aminopentyl)carbamate (0.2 mL, 1.0 mmol, 1.1 equiv) were put in a
microwave tube and dissolved in acetonitrile (1.5 mL). DIPEA (0.3
mL, 1.7 mmol) was added, and the tube was charged with a stirring
bar, sealed, and heated at 70 °C for 1.5 h. After 1.5 h, HPLC analysis
indicated full conversion. The mixture was concentrated, and EtOAc
(50 mL) and HCl (1 M in H2O, 50 mL) were added for extraction.
The organic layer was washed with H2O (50 mL) and brine (50 mL).
After drying over MgSO4, the solvent was removed in vacuo to give
the title compound as a yellow foam (186 mg, 0.46 mmol, 46% yield).
1H NMR (DMSO-d6, 400 MHz,) δ 8.48−7.96 (m, 2H), 7.86 (s, 1H),
7.48 (t, J = 5.1 Hz, rotamer, 0.38H), 7.41 (t, J = 5.7 Hz, rotamer,
0.62H), 7.10−7.01 (m, 1H), 6.77 (t, J = 5.0 Hz, 1H), 6.67 (dd, J =
3.0, 1.7 Hz, 1H), 3.28−3.17 (m, 2H), 2.90 (d, J = 6.6 Hz, 2H), 1.57−
1.44 (m, 2H), 1.44−1.21 (m, 13H).
N5-(4-Aminobutyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]-
triazine-5,7-diamine (8). TFA (4.3 mL, 57 mmol, 50 equiv) was
added to the suspension of Boc-protected amine 6 (444 mg, 1.14
mmol, 1 equiv) in DCM (equal volume as TFA). Solvents were
removed under reduced pressure after completion of the reaction (5
min). This gave the product as brown oil (899 mg, 1.13 mmol,
quantitative yield). Products were conﬁrmed by 1H NMR ﬁrst and
then stored under N2 until use.
1H NMR (DMSO-d6, 400 MHz): δ
8.49−8.05 (m, 3H (R-NH3+), 7.88 (dd, J = 1.7, 0.7 Hz, 1H), 7.62 (br
s, 3H (R-NH3
+)), 7.52 (t, J = 6.0 Hz, 1H), 7.09−7.02 (m, 1H), 6.68
(dd, J = 3.4, 1.7 Hz, 1H), 3.35−3.23 (m, 2H), 2.87−2.76 (m, 2H),
1.63−1.50 (m, 4H).
N5-(5-Aminopentyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]-
triazine-5,7-diamine (9). TFA (3 mL, 40 mmol, 50 equiv) was added
to the suspension of Boc-protected amine 7 (324 mg, 0.8 mmol, 1
equiv) in DCM. Once the reaction was completed, the solvent was
removed and the mixture was coevaporated twice with water and
dried using high vacuum. This gave a brown oil (556 mg, 0.8 mmol,
quantitative yield) as a TFA salt. The crude product was used without
further puriﬁcation.
tert-Butyl (5-Hydroxypentyl)carbamate (11). 5-Amino-1-pentanol
10 (4.2 mL, 38.8 mmol) was dissolved in DCM (20 mL). Di-tert-
butyl dicarbonate (8.4 g, 38.8 mmol) was slowly added as a solid. The
reaction was left stirring at rt for 18 h, and then the solvent was
removed to give a yellow oil (8.83 g, quantitative yield, some t-BuOH
left). 1H NMR (CDCl3, 400 MHz) δ 4.57 (s, 1H), 3.65 (t, J = 6.5 Hz,
2H), 3.13 (t, J = 6.5 Hz, 2H), 1.67−1.35 (m, 15H (under water
peak)).
tert-Butyl (5-Bromopentyl)carbamate (12). tert-Butyl (5-
hydroxypentyl)carbamate 11 (8.83 g, 38.8 mmol, 1eq) and PPh3
(15.3 g, 58.2 mmol, 1.5 equiv) were dissolved in THF (120 mL). A
solution of CBr4 (19.3 g, 58.2 mmol, 1.5 equiv) in THF (40 mL) was
added over 2 h using a syringe pump. After 3 h at room temperature,
the reaction mixture was ﬁltered and the ﬁltrate was concentrated.
This crude product was dissolved in DCM (∼5 mL) and puriﬁed by
ﬂash column chromatography (100% PE → 90% PE + 10% EtOAc).
This gave the product as a colorless oil (9.31 g, 35.0 mmol, 90%
yield). 1H NMR (400 MHz, CDCl3) δ 4.54 (s, 1H), 3.41 (t, J = 6.7
Hz, 2H), 3.13 (d, J = 5.9 Hz, 2H), 1.97−1.80 (m, 2H), 1.58−1.36 (m,
13H) ppm. 13C NMR (101 MHz, CDCl3) δ 40.5, 33.8, 32.5, 29.4,
28.6, 25.5.
tert-Butyl (5-(Prop-2-yn-1-ylamino)pentyl)carbamate (13). Prop-
argylamine (1 mL, 15 mmol, 3 equiv) was dissolved in acetonitrile (10
mL). To this stirred solution was added a solution of tert-butyl (5-
bromopentyl)carbamate 12 (798 mg, 3 mmol, 1 equiv) and DiPEA (1
mL, 6 mmol, 2 equiv) in acetonitrile (18 mL) using a syringe pump.
Afterward the solvent was removed and the product puriﬁed by ﬂash
column chromatography (EtOAc). This gave a yellowish oil (331 mg,
1.38 mmol, 46% yield) with EtOAc as an impurity. 1H NMR (CDCl3,
400 MHz) δ 4.54 (s, 1H), 3.44 (d, J = 2.0 Hz, 2H), 3.12 (q, J = 6.4
Hz, 2H), 2.70 (t, J = 7.1 Hz, 2H), 2.22 (t, J = 2.2 Hz, 1H), 1.55−1.34
(m, 15H) ppm.
tert-Butyl (5-(4-(Fluorosulfonyl)-N-(prop-2-yn-1-yl)benzamido)-
pentyl)carbamate (14). tert-Butyl (5-(prop-2-yn-1-ylamino)pentyl)-
carbamate 13 (664 mg, 1.38 mmol, 1 equiv) was dissolved in
acetonitrile (10 mL), and 4-ﬂuorosulfonyl benzoyl chloride (338 mg,
1.52 mmol, 1.1 equiv) was added and followed by the addition of
DiPEA (0.75 mL, 4.14 mmol, 3 equiv). Once the reaction was
completed, the solvent was removed and the crude mixture puriﬁed
by ﬂash column chromatography (DCM + 5% MTBE → DCM +
7.5% MTBE). This yielded a yellow oil (586 mg, 1.52 mmol,
quantitative yield). 1H NMR (DMSO-d6, 332 K, 400 MHz) δ 8.19 (d,
J = 8.0 Hz, 2H), 7.77 (d, J = 7.9 Hz, 2H), 6.37 (s, 1H), 4.16 (s, 2H),
3.37 (s, 2H), 3.15 (s, 1H), 2.90 (s, 2H), 1.61 (s, 2H), 1.44−1.29 (m,
9H), 1.29−1.14 (m, 4H), 1.11 (d, J = 16.6 Hz, 2H).
Biology. The radioligand [3H]ZM241385 with a speciﬁc activity
of 50 Ci mmol−1 was purchased from ARC Inc. (St. Louis, MO).
Unlabeled ZM241385 was a kind gift from Dr. S. M. Poucher (Astra
Zeneca, Macclesﬁeld, UK). 5′-N-Ethylcarboxamidoadenosine
(NECA) was purchased from Sigma-Aldrich (Steinheim, Germany).
Adenosine deaminase (ADA) was purchased from Sigma-Aldrich
Chemie N.V. Bicinchoninic acid (BCA) and BCA protein assay
reagent were obtained from Pierce Chemical Company (Rockford,
IL). Human embryonic kidney (HEK) 293 cells stably expressing the
hA2A receptor (hA2AR-WT) were kindly provided by Dr. J. Wang
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(Biogen/IDEC, Cambridge, MA). The puriﬁed hA2A receptor
material was kindly provided by Dr. Niek Dekker and Dr. Euan
Gordon (AstraZeneca). All other chemicals were of analytical grade
and obtained from standard commercial sources.
Cell Culture, Transfection, and Membrane Preparation. We
followed the procedures reported previously.13,37 Brieﬂy, HEK293
cells were grown as monolayers in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 2 mM glutamine, 10% newborn calf
serum, 50 μg mL−1 streptomycin, and 50 IU mL−1 penicillin at 37 °C
and 7% CO2 atmosphere. Cells were subcultured twice a week at a
ratio of 1:20 on 10 cm ⌀ culture plates. The cells were transfected
with pcDNA3.1(−) plasmid containing the hA2AR with N-terminal
FLAG and C-terminal His tags (FLAG-hA2AR-His
4) using the
calcium phosphate precipitation method (1 μg of plasmid DNA),
followed by a 48-h incubation, as previously described.38 Stably
transfected hA2AR-WT cells were grown in the same medium but with
the addition of G-418 (500 mg mL−1). Both transiently transfected
cells and stably transfected hA2AR-WT cells were detached from the
plates by scraping them into PBS and centrifuged to remove PBS
buﬀer. The pellets were resuspended in ice-cold Tris-HCl buﬀer (50
mM, pH 7.4) and then homogenized. The cell membrane suspensions
were centrifuged at 100 000g at 4 °C for 20 min, after which the
procedure was repeated one more time. After this, the same Tris-HCl
buﬀer was used to resuspend the pellet, and adenosine deaminase was
added to break down endogenous adenosine. HEK293 cells stably
expressing hA2AR were grown as monolayers in the same culture
medium and detached from plates by the same treatment for
membrane preparation. Both membranes were stored in 250 μL
aliquots at −80 °C until further use. Membrane protein concen-
trations were measured using the BCA method.39
[3H]ZM241383 Radioligand Displacement Assay. Radioligand
displacement experiments were performed as previously described.13
hA2AR-WT cell membrane aliquots containing 10 μg of protein were
incubated in a total volume of 100 μL of assay buﬀer to obtain an
assay window of approximately 3000 DPM of receptor-speciﬁc
radioligand binding. Nonspeciﬁc binding was determined in the
presence of 100 μM NECA and represented less than 10% of the total
binding. Brieﬂy, to each tube were added 25 μL of cell membranes
(10 μg of protein), 25 μL of radioligand [3H]ZM241383, 25 μL of
assay buﬀer [25 mM Tris-HCl, pH 7.4 at 25 °C, supplemented with 5
mM MgCl2 and 0.1% (w/v) CHAPS], and 25 μL of the indicated
compounds in increasing concentrations in the same assay buﬀer. The
mixture was incubated at 25 °C for 60 min to reach equilibrium.
Incubations were terminated by rapid vacuum ﬁltration to separate
the bound and free radioligand through 96-well GF/B ﬁlter plates
using a PerkinElmer Filtermate-harvester (PerkinElmer, Groningen,
Netherlands). Filters were subsequently washed three times with 2
mL of ice-cold buﬀer (25 mM Tris-HCl, pH 7.4, supplemented with 5
mM MgCl2). The ﬁlter-bound radioactivity was determined by
scintillation spectrometry using a P-E 1450 Microbeta Wallac Trilux
scintillation counter (PerkinElmer).
Heterologous Displacement Binding of Probe 4 and
ZM241385 to hA2AR-WT Cell Membranes. To assess the
irreversible binding level, cell membranes stably expressing hA2AR
were incubated with either 50 mM Tris-HCl (pH = 7.4) or two
concentrations (0.3 IC50 and IC50) of probe 4 or ZM241385 for 3 h at
25 °C on an Eppendorf Thermomixer. Subsequently, the mixture was
centrifuged at 16 100g at 4 °C for 5 min, and the supernatant was
removed, followed by a resuspension of the pellet in 1 mL of assay
buﬀer and spun again for 5 min at 16 100g at 4 °C. This washing
procedure was repeated three times. The 50 μL aliquots of these
pretreated membranes were incubated with 25 μL of radioligand
[3H]ZM241383 and 25 μL of a concentration range (100 pM to 1
μM) of unlabeled ZM241385 for 1 h at 25 °C. Incubation was
terminated as described under [3H]ZM241385 radioligand displace-
ment assay.
Expression and Puriﬁcation of Wild-Type hA2AR. The gene
coding for hA2AR (residues 1−316) was synthesized by Genscript and
cloned into pPICZb with an N-terminal α-factor signal sequence from
Saccharomyces cerevisiae (MRFPSIFTAVLFAASSLAAPVNTT-
EDETAQIPAAVIGYSDLEDFDVAVLPSNSTNNGLLINTTIASIAA-
EEGVSLERLVPRGS), followed by hA2AR and a C-terminus
biotinylation domain from Propionibacterium shermanii
(TSEFENLYQGQFGGGTG APAPAAGGAGGKAGEGEIPA-
L A G T V S K I L V E GD T V K AGQV L V L E AMKME E I N A
PTDGKVEKVLKERDAVQGQGLIKI) for enhanced expression40
and a decaHis tag (GHHHHHHHHHGS).
The receptor was expressed in Pichia pastoris SMD1168 at 3 L scale
in a fermentor essentially as described,41 except that dissolved oxygen
was maintained at 25%, and 2.5% DMSO and 10 mM theophylline
were included in the fermentation media. Approximately 200 g of wet
cells were harvested per liter. Cells (200 g) were resuspended using a
Turax in 600 mL ice-cold lysis buﬀer (50 mM HEPES pH 7.4, 200
mM NaCl, Complete EDTA free protease inhibitor tablets (Roche) at
1/50 mL). Cells were lysed by a single passage through a Constant
Cell system at 30 kpsi with extensive cooling. Cell debris was removed
by centrifugation at 1000g for 10 min at 4 °C. Membranes were
collected by ultracentrifugation at 100 000g for 45 min at 4 °C.
Membrane pellet was resuspended in buﬀer to a total protein
concentration of 20 mg mL−1 (ﬁnal volume of 180 mL) and stored at
−80 °C.
Membranes (20 mL) were resuspended in 200 mL of solubilization
buﬀer (25 mM HEPES, pH7.4, 300 mM NaCl, 20% glycerol, 1%
DDM/0.1% CHS, Complete tablets (1/50 mL), 200 μM theophyl-
line). The suspension was incubated for 2 h at 4 °C on a rolling table,
prior to centrifugation for 30 min at 100 000g to remove unsolubilized
material. Imidazole was added to a ﬁnal concentration of 15 mM, and
the clariﬁed solution was loaded on a 5 mL HisTrap crude column at
2.5 mL min−1. The column was washed with 100 mL buﬀer A (25
mM HEPES, 25 mM imidazole pH 7.4, 300 mM NaCl, 10% glycerol,
0.05% DDM/0.0005% CHS, 100 μM theophylline) to which
imidazole was added to ﬁnal concentration of 25 mM to reduce
nonspeciﬁc binding, followed by stepwise washes with increasing
concentrations of imidazole in this buﬀer (50 mM and 75 mM), and
hA2AR was eluted in 25 mM HEPES pH 7.4, 300 mM NaCl, 10%
glycerol, 0.05% DDM/0.0005%CHS, 300 mM imidazole, 100 μM
theophylline. Fractions were analyzed on SDS-PAGE, and those
containing hA2AR were pooled and concentrated to 2.5 mL using a 50
kDa ﬁlter. High concentrations of imidazole are harmful to hA2AR,
and the buﬀer was changed to buﬀer A on a PD10 G25 column. The
eluted fraction was further concentrated to 0.5 mL and loaded on a
Superdex-200 10/30 column running in 25 mM NaPi pH 7.2, 100
mM NaCl, 10 μM LMNG, 500 μM caﬀeine. Fractions were analyzed
on SDS-PAGE. hA2AR eluted as single peak at expected position for
the detergent−protein complex (around 80 kDa). Fractions were
pooled and concentrated on a 50 kDa ﬁlter to ﬁnal volume of 0.4 mL
and stored at −80 °C. Protein concentration was determined using
absorbance measurement against buﬀer A (Abs280(0.1%) = 1.05).
Final concentration was 7 mg mL−1 with a total of ∼2 mg hA2AR.
Aﬃnity-Based Protein Labeling Assay on Puriﬁed hA2AR
with Probe 4. For puriﬁed hA2AR, both aﬃnity labeling and click
reactions were performed on ice, unless indicated otherwise. Puriﬁed
hA2AR was diluted to a concentration of 0.1 mg mL
−1 in assay buﬀer
(25 mM HEPES pH 7.5, 100 mM NaCl, and 10 μM LMNG). The 38
μL samples were incubated with 2 μL of probe 4 at indicated
concentrations or vehicle control (1% DMSO) for 1 h. To initiate the
click reaction, 5.6 mM CuSO4 (2.5 μL/reaction, from a 100 mM
stock solution in water) was mixed vigorously with 33 mM sodium
ascorbate (1.5 μL/reaction, freshly made as a 1 M stock solution in
water) to obtain a yellow mixture, followed by the immediate addition
of 1.1 mM THPTA (0.5 μL/reaction, from a 100 mM stock solution
in water) and 4.4 μM ﬂuorescent tag Cy3-azide (0.5 μL/reaction,
from a 400 μM stock solution in DMSO). The reaction mixtures were
incubated for 1 h and quenched with 15 μL 4×SDS loading buﬀer.
Proteins in the mixture were separated by SDS-PAGE on 10%
polyacrylamide gels. In-gel ﬂuorescence was detected with a
ChemiDoc MP system (605/50 ﬁlter). Proteins were transferred
from gel to a PVDF membrane by Trans-BlotTurbo (BioRad). Then
the membrane was washed in 20 mL of TBS for 10 min on a roller
bench, followed by a three times wash with TBST (PBS with 0.1%
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Tween-20). Afterward, the membrane was blocked in 5% (w/v)
nonfat milk for 1 h at room temperature and probed with rabbit-anti-
His antibody (Rockland)(1:1000 [v/v] dilution in blocking buﬀer)
overnight at 4 °C, washed three times again with TBST, and
incubated with goat-antirabbit IgG-HRP (1:5000 in 5% milk in
TBST; Santa Cruz) for 1 h at room temperature. After two wash
cycles in TBST and one in TBS, the blot was developed in the dark
using a 10 mL luminal solution, with 100 μL of ECL enhancer and 3
μL of H2O2. Chemiluminescence was visualized with ChemiDoc XRS
(BioRad).
Competitive Labeling Assays in Puriﬁed hA2AR by Probe 4.
Prior to the two-step labeling experiment, puriﬁed hA2AR was diluted
to a concentration of 0.1 mg mL−1 in assay buﬀer and incubated with
10 μM compound 1, ZM241385, or vehicle control (1% DMSO) for
1 h on ice, followed by labeling with 1 μM probe 4 for 0.5 h on ice.
Samples were then subjected to the click chemistry procedure using
the protocol described above.
Aﬃnity-Based Protein Labeling of Membranes Transiently
Overexpressing FLAG-hA2AR-His. FLAG-hA2AR-His membranes
were diluted to a concentration of 1 mg mL−1 in 50 mM Tris-HCl
(pH = 7.4 at 25 °C). Either 2 μL of probe 4 at indicated
concentrations (0.1 μM, 0.3 μM, 1 μM, and 3 μM) or vehicle control
(1% DMSO) was added to 38 μL samples for 1 h incubation at room
temperature. Then all samples were subjected to the click chemistry
conjugation reaction. The click reagents were added in the following
sequence: 4.4 μM ﬂuorescent Cy3-azide (0.5 μL/reaction, 400 μM
stock in DMSO) was added to the mixture followed by 33 mM
sodium ascorbate (1.5 μL/reaction, freshly made in 1 M stock in
water) and 1.1 mM THPTA (0.5 μL/reaction, 100 mM stock in
water). Finally, 5.6 mM CuSO4 (2.5 μL/reaction, 100 mM stock in
water) was added to start and run the cycloaddition reaction for 1 h at
room temperature. Then the reaction was quenched with 15 μL
4×SDS loading buﬀer and protein material denatured for 30 min at 37
°C. Proteins (60 μL sample) were separated by SDS-PAGE on 10%
polyacrylamide gels. In-gel ﬂuorescence was detected with the
ChemiDoc MP system (605/50 ﬁlter). Proteins were transferred
from gel to a PVDF membrane by Trans-BlotTurbo (BioRad). Then
the membrane was washed in 20 mL of TBS for 10 min on a roller
bench, followed by a three times wash with TBST (PBS with 0.1%
Tween-20). Then the membrane was blocked in 5% (w/v) nonfat
milk and incubated with mouse-anti-FLAG (Sigma) (1:5000 [v/v]
dilution in blocking buﬀer) as primary antibody. Thereafter, the
membrane was washed in TBST three times and incubated with goat-
antimouse HRP (Sigma) (1:5000 [v/v] dilution in blocking buﬀer) as
secondary antibody. After two wash cycles in TBST and one in TBS,
the blot was developed in the dark using a 10 mL luminal solution,
with 100 μL of ECL enhancer and 3 μL of H2O2. Chemiluminescence
was imaged using a ChemiDoc XRS (BioRad).
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